129 related articles for article (PubMed ID: 18489502)
1. The estimation power of alternative comorbidity indices.
Baser O; Palmer L; Stephenson J
Value Health; 2008; 11(5):946-55. PubMed ID: 18489502
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.
Huber CA; Agosti R; Näpflin M; Blozik E
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):279-287. PubMed ID: 31828875
[TBL] [Abstract][Full Text] [Related]
3. ASA grade and Charlson Comorbidity Index of spinal surgery patients: correlation with complications and societal costs.
Whitmore RG; Stephen JH; Vernick C; Campbell PG; Yadla S; Ghobrial GM; Maltenfort MG; Ratliff JK
Spine J; 2014 Jan; 14(1):31-8. PubMed ID: 23602377
[TBL] [Abstract][Full Text] [Related]
4. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
6. Assessing measures of comorbidity and functional status for risk adjustment to compare hospital performance for colorectal cancer surgery: a retrospective data-linkage study.
Dobbins TA; Badgery-Parker T; Currow DC; Young JM
BMC Med Inform Decis Mak; 2015 Jul; 15():55. PubMed ID: 26174550
[TBL] [Abstract][Full Text] [Related]
7. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
[No Abstract] [Full Text] [Related]
8. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR
J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712
[No Abstract] [Full Text] [Related]
9. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
10. Development of an epilepsy-specific risk adjustment comorbidity index.
St Germaine-Smith C; Liu M; Quan H; Wiebe S; Jette N
Epilepsia; 2011 Dec; 52(12):2161-7. PubMed ID: 22004000
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic, pharmacy-based, and self-reported health measures in risk equalization models.
Stam PJ; van Vliet RC; van de Ven WP
Med Care; 2010 May; 48(5):448-57. PubMed ID: 20393368
[TBL] [Abstract][Full Text] [Related]
12. Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus.
Jönsen A; Clarke AE; Joseph L; Belisle P; Bernatsky S; Nived O; Bengtsson AA; Sturfelt G; Pineau CA
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1233-7. PubMed ID: 21618451
[TBL] [Abstract][Full Text] [Related]
13. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
14. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
Bera R; Offord S; Zubek D; Lau G; Lin J; Baker RA; Karson C
J Med Econ; 2013; 16(4):522-8. PubMed ID: 23360177
[TBL] [Abstract][Full Text] [Related]
15. Is the Charlson Comorbidity Index useful for predicting trauma outcomes?
Gabbe BJ; Magtengaard K; Hannaford AP; Cameron PA
Acad Emerg Med; 2005 Apr; 12(4):318-21. PubMed ID: 15805322
[TBL] [Abstract][Full Text] [Related]
16. The Charlson comorbidity index as a predictor of outcomes in liver transplantation: single-center experience.
Grosso G; di Francesco F; Vizzini G; Mistretta A; Pagano D; Echeverri GJ; Spada M; Basile F; Gridelli B; Gruttadauria S
Transplant Proc; 2012 Jun; 44(5):1298-302. PubMed ID: 22664004
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
18. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of the Charlson comorbidity index on mortality following acute pulmonary embolism.
Ng AC; Chow V; Yong AS; Chung T; Kritharides L
Respiration; 2013; 85(5):408-16. PubMed ID: 23147354
[TBL] [Abstract][Full Text] [Related]
20. The Charlson comorbidity index (CCI) for adjustment of hip fracture mortality in the elderly: analysis of the importance of recording secondary diagnoses.
Souza RC; Pinheiro RS; Coeli CM; Camargo KR
Cad Saude Publica; 2008 Feb; 24(2):315-22. PubMed ID: 18278278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
